Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Russell E Lewis

Showing results (121-130 of 225) with videos related to

Pageof 23
Sort By:
Antimicrobial Agents and Chemotherapy|July 29, 2009
Culture medium composition affects the lethality of Cunninghamella bertholletiae in a fly model of mucormycosisGeorgios N Pongas, Ronen Ben-Ami, Russell E Lewis, et al.
Clinical Therapeutics|November 24, 2007
Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: a retrospective, nonrandomized autopsy studyGeorgios Chamilos, Mario Luna, Russell E Lewis, et al.
Antimicrobial Agents and Chemotherapy|March 5, 2014
Effectiveness of primary anti-Aspergillus prophylaxis during remission induction chemotherapy of acute myeloid leukemiaMarisa Z R Gomes, Ying Jiang, Victor E Mulanovich, et al.
Antimicrobial Agents and Chemotherapy|November 27, 2013
Incidence density of invasive fungal infections during primary antifungal prophylaxis in newly diagnosed acute myeloid leukemia patients in a tertiary cancer center, 2009 to 2011Marisa Z R Gomes, Victor E Mulanovich, Y Jiang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 17, 2012
How does antifungal pharmacology differ for mucormycosis versus aspergillosis?Russell E Lewis, Olivier Lortholary, Brad Spellberg, et al.
The Journal of Infectious Diseases|April 6, 2021
Reply to Day et alMelissa D Johnson, Russell E Lewis, Elizabeth S Dodds Ashley, et al.
Antimicrobial Agents and Chemotherapy|December 30, 2009
Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosisRussell E Lewis, Nathan D Albert, Guangling Liao, et al.
The Journal of Infection|November 22, 2011
Rare opportunistic (non-Candida, non-Cryptococcus) yeast bloodstream infections in patients with cancerMaria N Chitasombat, Diamantis P Kofteridis, Ying Jiang, et al.
The Journal of Antimicrobial Chemotherapy|January 26, 2013
High-dose induction liposomal amphotericin B followed by de-escalation is effective in experimental Aspergillus terreus pneumoniaRussell E Lewis, Nathaniel P Albert, Guangling Liao, et al.
The Journal of Infectious Diseases|December 18, 2012
Tacrolimus enhances the potency of posaconazole against Rhizopus oryzae in vitro and in an experimental model of mucormycosisRussell E Lewis, Ronen Ben-Ami, Leyla Best, et al.
Pageof 23

Showing results (121-130 of 225) with videos related to

Sort By:
Pageof 23
Antimicrobial Agents and Chemotherapy|July 29, 2009
Culture medium composition affects the lethality of Cunninghamella bertholletiae in a fly model of mucormycosisGeorgios N Pongas, Ronen Ben-Ami, Russell E Lewis, et al.
Clinical Therapeutics|November 24, 2007
Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: a retrospective, nonrandomized autopsy studyGeorgios Chamilos, Mario Luna, Russell E Lewis, et al.
Antimicrobial Agents and Chemotherapy|March 5, 2014
Effectiveness of primary anti-Aspergillus prophylaxis during remission induction chemotherapy of acute myeloid leukemiaMarisa Z R Gomes, Ying Jiang, Victor E Mulanovich, et al.
Antimicrobial Agents and Chemotherapy|November 27, 2013
Incidence density of invasive fungal infections during primary antifungal prophylaxis in newly diagnosed acute myeloid leukemia patients in a tertiary cancer center, 2009 to 2011Marisa Z R Gomes, Victor E Mulanovich, Y Jiang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 17, 2012
How does antifungal pharmacology differ for mucormycosis versus aspergillosis?Russell E Lewis, Olivier Lortholary, Brad Spellberg, et al.
The Journal of Infectious Diseases|April 6, 2021
Reply to Day et alMelissa D Johnson, Russell E Lewis, Elizabeth S Dodds Ashley, et al.
Antimicrobial Agents and Chemotherapy|December 30, 2009
Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosisRussell E Lewis, Nathan D Albert, Guangling Liao, et al.
The Journal of Infection|November 22, 2011
Rare opportunistic (non-Candida, non-Cryptococcus) yeast bloodstream infections in patients with cancerMaria N Chitasombat, Diamantis P Kofteridis, Ying Jiang, et al.
The Journal of Antimicrobial Chemotherapy|January 26, 2013
High-dose induction liposomal amphotericin B followed by de-escalation is effective in experimental Aspergillus terreus pneumoniaRussell E Lewis, Nathaniel P Albert, Guangling Liao, et al.
The Journal of Infectious Diseases|December 18, 2012
Tacrolimus enhances the potency of posaconazole against Rhizopus oryzae in vitro and in an experimental model of mucormycosisRussell E Lewis, Ronen Ben-Ami, Leyla Best, et al.
Pageof 23